open access

Vol 27, No 4 (2023)
Review paper
Published online: 2023-12-13
Get Citation

Latest findings on labetalol in severe hypertension during pregnancy and in postpartum — a systematic review

Maciej Makarewicz1, Jarosław D. Kasprzak1, Jan Z. Peruga1
·
Arterial Hypertension 2023;27(4):207-214.
Affiliations
  1. Department of Cardiology, Medical University of Lodz, Lodz, Poland

open access

Vol 27, No 4 (2023)
REVIEW
Published online: 2023-12-13

Abstract

Hypertension during pregnancy is a significant problem, with severe hypertension being an especially dangerous condition. As pharmacological treatment options are limited mostly due to the unknown effects of multiple drugs on the fetus, labetalol is one of the more frequently used therapies. The other popular substances are methyldopa, nifedipine and hydralazine. In this paper, the effectiveness and limitations of labetalol in hypertensive disorders of pregnancy are discussed based on the latest available original papers. As the accessible data implicates, labetalol has a high and proven ability to reduce blood pressure with non-severe side effects. The most common of which are headaches and nausea. The drug seems to be slightly less effective in blood pressure normalization than nifedipine, with inconclusive data about safety to the mother and her baby. However due to a small number of patients included in the presented studies, more high-population trials are necessary to give an unambiguous recommendation on its regular usage.

Abstract

Hypertension during pregnancy is a significant problem, with severe hypertension being an especially dangerous condition. As pharmacological treatment options are limited mostly due to the unknown effects of multiple drugs on the fetus, labetalol is one of the more frequently used therapies. The other popular substances are methyldopa, nifedipine and hydralazine. In this paper, the effectiveness and limitations of labetalol in hypertensive disorders of pregnancy are discussed based on the latest available original papers. As the accessible data implicates, labetalol has a high and proven ability to reduce blood pressure with non-severe side effects. The most common of which are headaches and nausea. The drug seems to be slightly less effective in blood pressure normalization than nifedipine, with inconclusive data about safety to the mother and her baby. However due to a small number of patients included in the presented studies, more high-population trials are necessary to give an unambiguous recommendation on its regular usage.

Get Citation

Keywords

labetalol; severe hypertension; hypertension; pregnancy; gestation

About this article
Title

Latest findings on labetalol in severe hypertension during pregnancy and in postpartum — a systematic review

Journal

Arterial Hypertension

Issue

Vol 27, No 4 (2023)

Article type

Review paper

Pages

207-214

Published online

2023-12-13

Page views

536

Article views/downloads

245

DOI

10.5603/ah.97679

Bibliographic record

Arterial Hypertension 2023;27(4):207-214.

Keywords

labetalol
severe hypertension
hypertension
pregnancy
gestation

Authors

Maciej Makarewicz
Jarosław D. Kasprzak
Jan Z. Peruga

References (45)
  1. Garovic VD, Dechend R, Easterling T, et al. American Heart Association Council on Hypertension; Council on the Kidney in Cardiovascular Disease, Kidney in Heart Disease Science Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association. Hypertension. 2022; 79(2): e21–e41.
  2. Garovic VD, White WM, Vaughan L, et al. Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy. J Am Coll Cardiol. 2020; 75(18): 2323–2334.
  3. Olié V, Moutengou E, Grave C, et al. Prevalence of hypertensive disorders during pregnancy in France (2010-2018): The Nationwide CONCEPTION Study. J Clin Hypertens (Greenwich). 2021; 23(7): 1344–1353.
  4. Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann. 2014; 45(3): 301–314.
  5. Prejbisz A, Dobrowolski P, Kosiński P, et al. Management of hypertension in pregnancy: prevention, diagnosis, treatment and long‑term prognosis. Kardiol Pol. 2019; 77(7-8): 757–806.
  6. Brown MA, Magee LA, Kenny LC, et al. International Society for the Study of Hypertension in Pregnancy (ISSHP). The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018; 13: 291–310.
  7. Tooher J, Thornton C, Makris A, et al. Hypertension in pregnancy and long-term cardiovascular mortality: a retrospective cohort study. Am J Obstet Gynecol. 2016; 214(6): 722.e1–722.e6.
  8. Theilen LH, Meeks H, Fraser A, et al. Long-term mortality risk and life expectancy following recurrent hypertensive disease of pregnancy. Am J Obstet Gynecol. 2018; 219(1): 107.e1–107.e6.
  9. Theilen LH, Fraser A, Hollingshaus MS, et al. All-Cause and Cause-Specific Mortality After Hypertensive Disease of Pregnancy. Obstet Gynecol. 2016; 128(2): 238–244.
  10. Benschop L, Duvekot JJ, Roeters van Lennep JE. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart. 2019; 105(16): 1273–1278.
  11. Kilpatrick SJ, Abreo A, Greene N, et al. Severe maternal morbidity in a large cohort of women with acute severe intrapartum hypertension. Am J Obstet Gynecol. 2016; 215(1): 91.e1–91.e7.
  12. Gemechu KS, Assefa N, Mengistie B. Prevalence of hypertensive disorders of pregnancy and pregnancy outcomes in Sub-Saharan Africa: A systematic review and meta-analysis. Womens Health (Lond). 2020; 16: 1745506520973105.
  13. Kintiraki E, Papakatsika S, Kotronis G, et al. Pregnancy-Induced hypertension. Hormones (Athens). 2015; 14(2): 211–223.
  14. Al Khaja KAJ, Sequeira RP, Alkhaja AK, et al. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens. 2014; 32(3): 454–463.
  15. Alavifard S, Chase R, Janoudi G, et al. First-line antihypertensive treatment for severe hypertension in pregnancy: A systematic review and network meta-analysis. Pregnancy Hypertens. 2019; 18: 179–187.
  16. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013; 2013(7): CD001449.
  17. Magee LA, Abalos E, von Dadelszen P, et al. CHIPS Study Group. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol. 2011; 72(3): 394–401.
  18. Magee LA, von Dadelszen P. The management of severe hypertension. Semin Perinatol. 2009; 33(3): 138–142.
  19. Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2015; 125(2): 521–525.
  20. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(34): 3165–3241.
  21. Moroz LA, Simpson LL, Rochelson B. Management of severe hypertension in pregnancy. Semin Perinatol. 2016; 40(2): 112–118.
  22. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020; 135(6): e237–e260.
  23. B. Dhananjaya RJ. Oral nifedipine versus intravenous labetalol in hypertensive emergencies of pregnancy: a randomised trial, . Res J Pharm Biol Chem Sci. Res J Pharm Biol Chem Sci. 2015; 6(2): 1673–1681.
  24. Tariq S, Shahid A, Yousof T. Comparison of maternal hypotension after administration of labetalol versus hydralazine in treating patients having severe pregnancy induced hypertension. Pak J Med Health Sci. 2017; 11(2): 541–543.
  25. Haddaway NR, Page MJ, Pritchard CC, et al. : An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022; 18(2): e1230.
  26. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366: l4898.
  27. Shi DD, Yang FZ, Zhou L, et al. Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. J Clin Pharm Ther. 2016; 41(6): 657–661.
  28. Patel P, Koli D, Maitra N, et al. Comparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy. J Obstet Gynaecol India. 2018; 68(5): 376–381.
  29. Vigil-De Gracia P, Lasso M, Ruiz E, et al. or the HYLA treatment study. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006; 128(1-2): 157–162.
  30. Delgado De Pasquale S, Velarde R, Reyes O, et al. Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial. Pregnancy Hypertens. 2014; 4(1): 19–22.
  31. Khan A, Hafeez S, Nasrullah FD. Comparison of Hydralazine and Labetalol to lower severe hypertension in pregnancy. Pak J Med Sci. 2017; 33(2): 466–470.
  32. Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019; 394(10203): 1011–1021.
  33. Zulfeen M, Tatapudi R, Sowjanya R. Erratum to "IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial" [Eur. J. Obstet. Gynecol. Reprod. Biol. 236 (May) (2019) 46-52]. Eur J Obstet Gynecol Reprod Biol. 2020; 247: 272.
  34. Mukherjee S, Khan S, Jain U, et al. A comparative evaluation of intravenous labetalol versus oral nifedipine for control of severe pregnancy-induced hypertension with low-dose regimen. Int J Med Sci Public Health. 2016; 5(6): 1183.
  35. Dhali B, Bhattacharya S, Ganguly R, et al. A randomized trial of intravenous labetalol and oral nifedipine in severe pregnancy induced hypertension. Int J Reprod Contracept Obstet Gynecol. 2012: 42–46.
  36. Thalamati S, Bandaru S, Bhumireddy D. Assessment of safety and efficacy of oral nifedipine and intravenous labetalol in management of increased blood pressure in severe preeclampsia. Int J Reprod Contracept Obstet Gynecol. 2018; 7(7): 2645.
  37. Ainuddin J, Javed F, Kazi S. Oral labetalol versus oral nifedipine for the management of postpartum hypertension a randomized control trial. Pak J Med Sci. 2019; 35(5): 1428–1433.
  38. Raheem IA, Saaid R, Omar SZ, et al. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2012; 119(1): 78–85.
  39. Sathya Lakshmi B, Dasari P. Oral nifedipine versus intravenous labetalol in hypertensive urgencies and emergencies of pregnancy: a randomized clinical trial. Obstet Med. 2012; 5(4): 171–175.
  40. Victorino GP, Battistella FD, Wisner DH. Does tachycardia correlate with hypotension after trauma? J Am Coll Surg. 2003; 196(5): 679–684.
  41. Leuppi JD, Schnyder P, Hartmann K, et al. Drug-induced bronchospasm: analysis of 187 spontaneously reported cases. Respiration. 2001; 68(4): 345–351.
  42. Awaludin A, Rahayu C, Daud NA, et al. Antihypertensive Medications for Severe Hypertension in Pregnancy: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2022; 10(2).
  43. Shi Q, Leng W, Yao Q, et al. Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy. Int J Cardiol. 2015; 178: 162–164.
  44. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries- a systematic review. Int J Equity Health. 2018; 17(1): 37.
  45. Stott D, Bolten M, Paraschiv D, et al. Maternal ethnicity and its impact on the haemodynamic and blood pressure response to labetalol for the treatment of antenatal hypertension. Open Heart. 2016; 3(1): e000351.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl